Search results
Added:
6 months ago
AHA Scientific Sessions 2025 - Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) joins us to discuss the evolving understanding of the causal relationship between elevated lipoprotein(a) and atherosclerotic cardiovascular disease, and what this means for risk stratification and management strategies in clinical practice.Dr O'Donoghue begins by highlighting the importance for clinicians to…
View more
Added:
1 year ago
ECO 2024 — Prof Sven Francque (University of Antwerp, BE) joins us to talk about the new EASL-EASD-EASO Practice Guidelines for MAFLD.In this interview, Prof Francque highlights some of the unmet needs in people with MAFLD (formerly known as NAFLD). He then summarises the key highlights of the latest guidelines, including guidance on treatment options. He also discusses some of the challenges…
View more
Added:
1 month ago
ACC 2026 — Dr Deepak Bhatt (Mount Sinai Fuster Heart Hospital, US) delivers his expert verdict on three late-breaking clinical trials from ACC 2026 that are poised to influence cardiovascular care and future clinical guidelines.Dr Bhatt highlights data updates from the SURPASS-CVOT trial, exploring expanded cardiometabolic findings with tirzepatide versus dulaglutide, discusses the HI-PEITHO…
View more
Added:
1 month ago
ACC 2026 — Drs Karim Al-Azizi (Baylor Scott & White The Heart Hospital, Plano) and Babar Basir (Henry Ford Hospital, US) deliver a short, front-line interventional view of the STEMI Door-to-Unload (STEMI-DTU) trial (NCT03000270), making this an efficient 5-minute update for cardiologists and cath lab teams.STEMI-DTU randomised haemodynamically stable patients aged 18–85 years with a first acute…
View more
Added:
8 months ago
ESC Congress 2025 - Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Professor Jeanine Roeters van Lennep (Erasmus Medical Center, NL) to discuss the 2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias.This focused update delivers the most current, evidence-based recommendations for lipid management and cardiovascular risk…
View more
Added:
8 months ago
ESC Congress 2025 - New guidelines for catheter-based VTE therapy emphasise the importance of involving vascular experts, and performing procedures in experienced centers.Dr Oliver Schlager (Medical University of Vienna, AT) joins us to discuss the newly released 2025 ESVM Guidelines on Interventional Treatment of Venous Thromboembolism, endorsed by European national societies of Vascular…
View more
Added:
8 months ago
ESC Congress 2025 - Dr Harriette Van Spall (McMaster University, Canada) sits down with Professor Michael Borger (University of Leipzig Heart Center, Germany), Co-Chair of the newly released 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease.The new guidelines bring together the latest evidence and expert consensus on how to diagnose, evaluate, and treat patients with valvular…
View more
Added:
2 months ago
Dr Tom De Potter (Cardiovascular Center, OLV Hospital, Aalst, BE) joins us to share his expert perspective on the five key developments poised to transform atrial fibrillation and electrophysiology practice in 2026.This forward-looking discussion examines emerging technologies, evolving clinical evidence, and shifting treatment paradigms that will influence day-to-day decision-making in…
View more
Added:
3 months ago
Arrhythmia Academy Editor-in-Chief Dr Luigi Di Biase shares his expert perspective on the most practice-changing clinical trials emerging from the latest advances in atrial fibrillation management.In this highlights discussion, Dr Di Biase distills the key evidence that is reshaping clinical decision-making in AF ablation, anticoagulation strategies, and rhythm control approaches. Drawing from…
View more
Added:
6 months ago
AHA Scientific Sessions 2025 - Dr Nils Krüger (Brigham and Women's Hospital, US) joins us to discuss findings from the TIRZSEMA-CVOT (NCT07096063) study, examining real-world cardiovascular outcomes with tirzepatide and semaglutide in patients with type 2 diabetes at cardiovascular risk.This retrospective cohort study utilized three national US claims databases to evaluate over 887,000 patients…
View more